Skip to main content
Terug
Watch Compare

Renalytix plc

Datakwaliteit: 100%
Ook genoteerd als RENXF OTC
RNLXY
OTC Services Health Services
€ 1,40
▲ € 0,02 (1,45%)
Marktkapitalisatie: 305,91 M
Prijs
€ 1,40
Marktkapitalisatie
305,91 M
Dagbereik
€ 1,35 — € 1,35
52-Weeksbereik
€ 1,31 — € 202,50
Volume
2.192
Openen € 1,35
50D / 200D Gem.
€ 2,69
48,00% below
50D / 200D Gem.
€ 78,13
98,21% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -24,44 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-32,74%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-1191,75%
Op. Margin-1054,93%

Veiligheid

Debt / Equity
N/A
Current Ratio0,24
Interest CoverageN/A

Waardering

PE (TTM)
-10,91
Onder sectorgemiddelde (-1,17)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Services sector mediaan (502 peers)
Metriek Aandeel Sector Mediaan
P/E -10,9 -1,2
P/B 1,4
ROE % -16,0
Net Margin % -1191,8 -19,4
Rev Growth 5Y % 4,0
D/E 0,4

All Fundamental Metrics

Growth
Revenue Growth (1Y) -32,74% Revenue Growth (3Y) -12,21%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,35 M Net Income (TTM) -28,03 M
ROE N/A ROA -413,33%
Gross Margin 12,71% Operating Margin -1054,93%
Net Margin -1191,75% Free Cash Flow (TTM) -24,44 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,24
Interest Coverage N/A Asset Turnover 0,35
Working Capital -9,13 M Tangible Book Value -12,19 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10,91 Forward P/E N/A
P/B Ratio N/A P/S Ratio 130,07
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7,99%
Market Cap 305,91 M Enterprise Value 305,00 M
Per Share
EPS (Diluted TTM) -0,24 Revenue / Share 0,01
FCF / Share -0,11 OCF / Share -0,11
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 87,20%
SBC-Adj. FCF -25,99 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 2,29 M 3,40 M 2,97 M 1,49 M
Net Income -33,46 M -45,61 M -45,28 M -35,34 M -9,84 M
EPS (Diluted) -0,31 -0,55 -0,67
Gross Profit 156.000,0 720.000,0 874.000,0 633.000,0
Operating Income -29,61 M -42,22 M -53,18 M -31,92 M -10,32 M
EBITDA
R&D Expenses
SG&A Expenses
D&A 364.000,0 508.000,0 489.000,0 282.000,0 70.000,0
Interest Expense
Income Tax 4.000,0 2.000,0 25.000,0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 7,97 M 30,63 M 50,07 M 78,58 M 20,83 M
Total Liabilities 15,83 M 23,66 M 19,46 M 7,12 M 4,97 M
Shareholders' Equity -7,85 M 6,97 M 30,61 M 71,46 M 15,91 M
Total Debt
Cash & Equivalents 4,68 M 24,68 M 41,33 M 65,13 M 13,29 M
Current Assets 6,12 M 26,88 M 44,75 M 66,79 M 14,84 M
Current Liabilities 11,50 M 16,14 M 11,78 M 7,06 M 3,29 M